Milestone Pharmaceuticals stock falls 6.41 percent after Q2 miss
Published on 09/24/2026 at 07:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Milestone Pharmaceuticals stock fell 6.41 percent to USD 0.86 on Nasdaq on September 23, 2026, leaving the shares 71.90 percent below their 52-week high of USD 3.06. The latest quarterly comparison shows why commercialization and cash generation remain central to the valuation.
China approval adds milestone cash
On September 3, 2026, Milestone Pharmaceuticals said China's National Medical Products Administration approved etripamil nasal spray for adults with paroxysmal supraventricular tachycardia. The decision marked etripamil's first regulatory approval outside the United States and triggered a USD 2.0 million milestone payment.
The agreement with Everest Medicines also gives Milestone eligibility for up to USD 98.0 million in commercial and development milestones and tiered royalties of up to 18 percent on future Greater China sales. That structure adds a measurable source of potential non-product revenue while CARDAMYST expands beyond its initial market.
Revenue trails the consensus
For Q2 2026, revenue was USD 0.56 million, compared with USD 0.82 million expected by analysts, a USD 0.26 million shortfall. Adjusted? No. The reported EPS was a loss of USD 0.21 against a consensus loss of USD 0.20, a USD 0.01 miss, according to MarketBeat.
The contrast is important: regulatory progress is producing milestone economics, while quarterly product revenue remains below expectations. The stock's USD 0.86 level is also only USD 0.01 above its 52-week low of USD 0.85, making execution in the commercial rollout the key operating variable.
Stock stays near its yearly low
Milestone Pharmaceuticals stock stood at USD 0.86 on Nasdaq on September 23, 2026. Market capitalization was USD 107.3 million, while reported volume reached 1,497,430 shares.
Milestone Pharmaceuticals at a glance
- Company: Milestone Pharmaceuticals Inc.
- Ticker: MIST
- Trading venue: Nasdaq
- Price as of September 23, 2026: USD 0.86
- Market capitalization: USD 107.3 million as of September 23, 2026
- 52-week range: USD 0.85-3.06 as of September 23, 2026
- Sector / Industry: Healthcare / Biotechnology
